A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) (clinicaltrials.gov) - Oct 8, 2026 - P1/2 | N=83 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Trial primary completion date: Jan 2027 ➔ Aug 2026
Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Natural Killer/T-cell Lymphoma • Non-Hodgkin's Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • ALK
|